
United Therapeutics Corporation UTHR
$ 570.05
0.51%
Annual report 2025
added 02-25-2026
United Therapeutics Corporation Depreciation & Amortization 2011-2026 | UTHR
Annual Depreciation & Amortization United Therapeutics Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 85.6 M | 72.5 M | 53.2 M | 51.3 M | 49.9 M | 49.9 M | 45.9 M | 35.9 M | 31 M | 31.6 M | 32.9 M | 32.2 M | 31.3 M | 27.1 M | 20.5 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 85.6 M | 20.5 M | 43.4 M |
Quarterly Depreciation & Amortization United Therapeutics Corporation
| 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 19.8 M | - | - | - | 15 M | - | - | - | 13.3 M | - | 38.1 M | - | 12.5 M | - | 37.3 M | - | 12.5 M | - | 36.8 M | 25 M | 12.4 M | - | 33.4 M | 20.7 M | 10.3 M | - | 25.4 M | 16 M | 7.9 M | - | 23.3 M | 15.6 M | 7.9 M | - | 23.8 M | 15.6 M | 7.7 M | - | 25 M | 16.7 M | 8.3 M | - | 23.3 M | 15.2 M | 7.56 M | - | 23.5 M | 15.8 M | 8.16 M | - | 19.9 M | 12.9 M | 6.65 M | - | 15.6 M | 10.6 M | 5.81 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 38.1 M | 5.81 M | 17.4 M |
Depreciation & Amortization of other stocks in the Biotechnology industry
| Issuer | Depreciation & Amortization | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Amphastar Pharmaceuticals
AMPH
|
31.6 M | $ 21.91 | 2.34 % | $ 1.02 B | ||
|
I-Mab
IMAB
|
23.9 M | - | - | $ 866 M | ||
|
Aeglea BioTherapeutics
AGLE
|
744 K | - | - | $ 1.01 B | ||
|
Aptorum Group Limited
APM
|
1.13 M | $ 0.94 | 5.23 % | $ 6.91 M | ||
|
ACADIA Pharmaceuticals
ACAD
|
920 K | $ 22.7 | 3.37 % | $ 3.76 B | ||
|
Advaxis
ADXS
|
369 K | - | -9.65 % | $ 45.9 M | ||
|
AIkido Pharma
AIKI
|
105 K | - | 1.93 % | $ 17.4 M | ||
|
Akouos
AKUS
|
2.49 M | - | 0.23 % | $ 488 M | ||
|
Allakos
ALLK
|
6.14 M | - | - | $ 28.6 M | ||
|
AlloVir
ALVR
|
13 K | - | 4.14 % | $ 49.1 M | ||
|
Ampio Pharmaceuticals
AMPE
|
122 K | - | -11.43 % | $ 502 K | ||
|
Applied Molecular Transport
AMTI
|
3.13 M | - | - | $ 10.1 M | ||
|
Aeterna Zentaris
AEZS
|
58 K | - | 5.93 % | $ 314 M | ||
|
Brainstorm Cell Therapeutics
BCLI
|
199 K | - | -2.5 % | $ 5.88 M | ||
|
Aptinyx
APTX
|
122 K | - | -39.0 % | $ 4.57 M | ||
|
AgeX Therapeutics
AGE
|
100 K | - | -10.17 % | $ 12.2 K | ||
|
Aravive
ARAV
|
886 K | - | -13.39 % | $ 1.45 M | ||
|
Aridis Pharmaceuticals
ARDS
|
487 K | - | 17.91 % | $ 11.1 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
1.51 M | - | - | $ 26.5 M | ||
|
Aquestive Therapeutics
AQST
|
548 K | $ 4.16 | 1.84 % | $ 445 M | ||
|
Arcutis Biotherapeutics
ARQT
|
700 K | $ 23.75 | 2.09 % | $ 3.02 B | ||
|
Ayala Pharmaceuticals
AYLA
|
162 K | - | - | $ 7.46 M | ||
|
Autolus Therapeutics plc
AUTL
|
8.3 M | $ 1.45 | 0.35 % | $ 386 M | ||
|
Aptose Biosciences
APTO
|
22 K | - | -45.71 % | $ 1.2 M | ||
|
AVROBIO
AVRO
|
617 K | - | 1083.1 % | $ 745 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
24 K | $ 3.03 | 4.12 % | $ 4.99 M | ||
|
BioDelivery Sciences International
BDSI
|
140 K | - | -4.8 % | $ 255 M | ||
|
BeiGene, Ltd.
BGNE
|
142 M | - | 0.49 % | $ 251 B | ||
|
Akero Therapeutics
AKRO
|
18 K | - | - | $ 3.67 B | ||
|
bluebird bio
BLUE
|
28 M | - | - | $ 546 M | ||
|
ContraFect Corporation
CFRX
|
154 K | - | -5.16 % | $ 5.39 M | ||
|
Cardiff Oncology
CRDF
|
364 K | $ 1.76 | 2.03 % | $ 118 M | ||
|
BioXcel Therapeutics
BTAI
|
300 K | $ 1.11 | 4.25 % | $ 13.6 M | ||
|
Cabaletta Bio
CABA
|
1.65 M | $ 3.02 | 2.43 % | $ 303 M | ||
|
Cara Therapeutics
CARA
|
95 K | - | -3.03 % | $ 260 M | ||
|
Allena Pharmaceuticals
ALNA
|
363 K | - | 3.16 % | $ 1.9 M | ||
|
CASI Pharmaceuticals
CASI
|
468 K | - | - | $ 35.4 M | ||
|
CymaBay Therapeutics
CBAY
|
681 K | - | - | $ 3.45 B |